• Dr. Sangeeta Kamthan

The number of commercially accessible antiepileptic medicines (AEDs) has significantly expanded in recent years. This may make management decisions more difficult, but it also presents some welcome new alternatives for efficiently individualizing care. Opportunities to customize medication therapy to the unique patient's features have never been stronger due to the fact that each of the current AEDs differs from others in many clinically significant qualities. Spectrum of efficacy in various seizure types, adverse effects profile, pharmacokinetic properties, susceptibility to cause or be a target of clinically important drug-drug interactions, ease of use, and cost are all factors that should be taken into consideration when choosing a drug for patients with epilepsy. Other elements that must be taken into account when choosing a medication include the accessibility of user-friendly paediatric formulations, and possibly positive impacts on human health. Among the most often administered centrally active medications are antiepileptic medicines (AEDs). AED use was discovered to be present in 5,426 people in a recent study of 471,873 people in Denmark, which represents a prevalence of 1.1%. [1]

Systematic Review on Anti-Epileptic Drugs

"Systematic Review on Anti-Epileptic Drugs", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.5, Issue 9, page no.1201-1206, September 2018, Available :http://www.jetir.org/papers/JETIR1809972.pdf

"Systematic Review on Anti-Epileptic Drugs", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.5, Issue 9, page no. pp1201-1206, September 2018, Available at : http://www.jetir.org/papers/JETIR1809972.pdf